SCHEMBL5455906

SCHEMBL5455906

COc1ccc(NC(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.74
MAPT P10636 5/20 0.67
THRB P10828 1/20 0.62
TP53 P04637 2/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
ALDH1A1 P00352 1/20 0.61
HPGD P15428 1/20 0.61
ALOX15 P16050 1/20 0.61
TSHR P16473 1/20 0.61
HSD17B10 Q99714 1/20 0.61
RAB9A P51151 1/20 0.61
ADORA3 P0DMS8 1/20 0.60
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
RXFP1 Q9HBX9 1/20 0.59
GLO1 Q04760 1/20 0.59
RECQL P46063 1/20 0.59
TLR2 O60603 1/20 0.59
TDP1 Q9NUW8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455677 0.89 FLT3 (0.74) FLT3MAPTTHRBALDH1A1HPGD
SCHEMBL5462791 0.87 FLT3 (0.72) FLT3MAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL5446246 0.87 FLT3 (0.73) FLT3MAPTTHRBALDH1A1HPGD
SCHEMBL5455976 0.87 KMT2A (0.64) FLT3MAPTALDH1A1RAB9AKMT2A
SCHEMBL4234573 0.86 FLT3 (0.72) FLT3MAPTTP53ALDH1A1RAB9A
SCHEMBL5455183 0.86 FLT3 (0.55) FLT3MAPTTHRBRAB9AKMT2A
SCHEMBL5458963 0.86 FLT3 (0.71) FLT3MAPTTHRBALDH1A1HPGD
SCHEMBL5455812 0.86 MAPT (0.58) FLT3MAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL5453159 0.86 FLT3 (0.55) FLT3MAPTTHRBSMN1; SMN2RAB9A
SCHEMBL5453610 0.85 FLT3 (0.77) FLT3MAPTSMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885MAPT 21/4885THRB 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.